Porter SB, et al. - A total of 38,220 patients (8,877 high-risk cases) who underwent primary TKA and THA between 2011 and 2017 were retrospectively reviewed by the researchers in order to discover the risk of complications between high-risk and low-risk TKA and THA patients who were receiving tranexamic acid (TXA). No notable variation in the odds of these adverse outcomes between high-risk patients who received TXA and high-risk patients who did not receive TXA was noted. Also, for high-risk patients who were receiving TXA vs high-risk patients who did not receive TXA, no variations when assessing odds of 90 days postoperative deep vein thrombosis and pulmonary embolism nor myocardial infarction and cerebrovascular accident were observed. Thus, TXA administration to high-risk TKA and THA patients is not correlated with a statistically important variation in adverse outcomes. Incremental evidence in support of TXA administration for high-risk patients who were undergoing primary arthroplasties was demonstrated.